Rigor Reviewed

Rigor-Reviewed Manuscript

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Name: Adcurare Rigor Record — Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
Item: Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.
Rating: 100
Author: Adcurare

Ma F, Yan M, Li W, Ouyang Q, Tong Z, Teng Y, Wang Y, Wang S, Geng C, Luo T, Zhong J, Zhang Q, Liu Q, Zeng X, Sun T, Mo Q, Zhou S, Li P, Cheng J, Wang X, Nie J, Yang J, Wu X, Wang X, Li H, Yao G, Fan Y, Lin J, Zhu X, Xu B

Paper source

Read full text (PMC)Journal

Embed this Rigor badge

Adcurare Rigor Review — 4★ (Strong), 0 critical, 3 high issues for “Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.”

Links back to this Rigor Record.

Adcurare Editorial

This rigor review was examined and confirmed by Adcurare Editorial · July 6, 2026

Adcurare Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★

Model-reported confidence: highReviewer agreement: highEngine: 7.6.0Source: full text

Problems surfaced2 types

Internal contradictions in the reported numbers
Other integrity concern

This Adcurare Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The manuscript reports a well-conducted phase 3 clinical trial with rigorous methodology, clear reporting, and adequate data sharing. Minor gaps include the absence of a CONSORT checklist, lack of explicit proportional hazards assumption verification, and a small internal inconsistency in the reported median follow-up.

This evaluation synthesizes three independent rigor reviews, a copyedit pass, and verification components covering citations, statistics, reproducibility, and integrity. The statistics verification covered only 11 tests with reported test statistics or effect estimates; p-values reported only as thresholds were not recomputed. No retracted or missing references were found. The integrity lens noted a minor internal contradiction in reported median follow-up (35.7 vs 35.9 months).

12 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 11 tests: 11 consistent, 0 inconsistent, 11 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction thoroughly reviews the role of HER2 in breast cancer, dual anti-HER2 therapy, and the prior CLEOPATRA trial. It explains pyrotinib's mechanism as an irreversible pan-HER inhibitor and its potential advantages. Limitations of prior work (e.g., preliminary overall survival data) are explicitly acknowledged and addressed by this updated analysis.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The scientific premise is well established with clear rationale, citing key prior studies (CLEOPATRA) and explaining how pyrotinib addresses gaps.

Evidence

direct quote[Introduction, paragraph 2]

“Among the dual anti-HER2 regimens, the combination of pertuzumab and trastuzumab along with docetaxel is the established standard of care for the initial treatment of patients with HER2 positive metastatic breast cancer, based on the landmark Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study.”

direct quote[Introduction, paragraph 3]

“Pyrotinib, a small molecule, irreversible, pan-HER receptor tyrosine kinase inhibitor has shown promising antitumour activity in both single agent and combination treatment settings.”

direct quote[Introduction, final paragraph]

“Although the interim analysis of the PHILA … showed promising results in terms of progression-free survival, the data for overall survival remained preliminary.”

PASSReviewer 2· 95% conf

The scientific premise is well-established, citing the CLEOPATRA trial as the standard of care and the rationale for dual HER2 blockade, and the PHILA interim analysis as the direct basis for this long-term follow-up.

Evidence

direct quote[Introduction, paragraph 2]

direct quote[Introduction, final paragraph]

“Here, we present the prespecified final analysis of progression-free survival results, including overall survival, duration of response, and safety results after a longer follow-up period, as well as long term survival outcomes.”

direct quote[Discussion, Limitations of this study]

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

PASSReviewer 3· 95% conf

The paper clearly establishes its scientific premise by citing the CLEOPATRA trial as the standard of care, describing the rationale for dual anti-HER2 blockade with pyrotinib, and referencing the prior interim analysis of the PHILA trial.

Evidence

direct quote[Introduction, paragraph 2]

direct quote[Introduction, paragraph 3]

“Pyrotinib, a small molecule, irreversible, pan-HER receptor tyrosine kinase inhibitor has shown promising antitumour activity in both single agent and combination treatment settings.”

direct quote[Discussion, 'Limitations of this study']

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

Randomisation was centralised via an interactive web response system with stratification factors. Blinding covered patients, investigators, and sponsor. A power analysis and sample size calculation are provided. Inclusion/exclusion criteria are explicitly listed. The analysis population is defined (full analysis set, safety set). Outlier handling is not explicitly discussed, but prespecified analysis methods (ITT, stratified log-rank, Cox models) are appropriate for a phase 3 trial. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingN/A

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 98% conf

The study design is rigorous: multicentre, double-blind, randomised, placebo-controlled, phase 3 trial with a prespecified sample size calculation, stratification, and centralised randomisation.

Evidence

direct quote[Methods, Procedures, paragraph 1]

“Randomisation was done through a centralised interactive web response system.”

direct quote[Methods, Procedures, paragraph 1]

“Patients, investigators, and the sponsor were blinded to treatment allocation.”

direct quote[Methods, Statistical analysis, paragraph 1]

“Based on an assumption of a median progression-free survival of 12.5 months … the study aimed to have 410 investigator assessed progression-free survival events to provide 80% power to detect a four month increase … at a one sided significance level of 0.025 for superiority.”

PASSReviewer 2· 95% conf

The study design is rigorous for a phase 3 clinical trial, with clear randomization, blinding, a pre-specified power analysis, and well-defined inclusion/exclusion criteria.

Evidence

direct quote[Methods, Procedures]

“Randomisation was done through a centralised interactive web response system.”

direct quote[Methods, Procedures]

“Patients, investigators, and the sponsor were blinded to treatment allocation.”

direct quote[Methods, Statistical analysis]

“Based on an assumption of a median progression-free survival of 12.5 months with trastuzumab and docetaxel, the study aimed to have 410 investigator assessed progression-free survival events to provide 80% power to detect a four month increase with the pyrotinib plus trastuzumab and docetaxel regimen (16.5 months, hazard ratio 0.76), at a one sided significance level of 0.025 for superiority.”

PASSReviewer 3· 90% conf

The study design is robust for a phase 3 clinical trial: it reports centralised randomisation with stratification, double blinding, a prespecified power analysis, inclusion/exclusion criteria, and a full analysis set.

Evidence

direct quote[Methods, 'Procedures']

“Randomisation was done through a centralised interactive web response system.”

direct quote[Methods, 'Statistical analysis']

direct quote[Methods, 'Study design and participants']

“Participants aged 18 to 75 years with histologically confirmed HER2 positive recurrent or metastatic breast cancer, who had not received the treatment for this stage of the disease were eligible.”

All participants are female (sex reported). Age range (18–75) and key health status (ECOG performance status 0-1, adequate organ function) are inclusion criteria. HER2 positivity status and hormone receptor status are defined. As this is a human trial, species/strain and housing conditions are not applicable.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Key human demographic and biological variables are well reported.

Evidence

direct quote[Methods, Study design and participants; Results, paragraph 1]

“Participants aged 18 to 75 years with histologically confirmed HER2 positive recurrent or metastatic breast cancer … were eligible.”

direct quote[Methods, Study design and participants]

“Other inclusion criteria included … Eastern Cooperative Oncology Group performance status (0 representing being fully active or 1 representing ability to carry out light or sedentary work), and adequate organ function.”

direct quote[Methods, Procedures, paragraph 1]

“Stratification factors included previous use of trastuzumab in neoadjuvant or adjuvant therapy (yes v no) and hormone receptor status …”

PASSReviewer 2· 95% conf

Key biological variables for a human clinical trial are adequately reported, including sex, age, and relevant disease characteristics.

Evidence

direct quote[Abstract, Participants]

“590 female patients with untreated HER2 positive metastatic breast cancer.”

direct quote[Methods, Study design and participants]

direct quote[Results, Patients]

“Previous reports have indicated that the baseline characteristics of participants were generally similar between the two groups.”

PASSReviewer 3· 90% conf

As a human clinical trial, sex (all female) is reported, age range is given, and baseline demographics including hormone receptor status and ECOG performance status are described. Sex justification is not applicable as the study focuses on breast cancer, which overwhelmingly affects women.

Evidence

direct quote[Abstract, 'Participants']

“590 female patients with untreated HER2 positive metastatic breast cancer.”

direct quote[Methods, 'Study design and participants']

“Participants aged 18 to 75 years with histologically confirmed HER2 positive recurrent or metastatic breast cancer.”

paraphrase[Results, paragraph 1]

“Baseline characteristics were generally similar between groups, but specific race/ethnicity data are not provided; the study was conducted in Chinese centres.”

The paper states approval by the ethics committee of each study centre and provides a reference to a supplementary table listing them. It confirms written informed consent from all patients and compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals, informed consent, and regulatory compliance are adequately reported.

Evidence

direct quote[Ethics statements, Ethical approval]

“This study was approved by the ethics committee of each study centre (see supplementary table S9) and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.”

direct quote[Methods, Study design and participants]

“All patients provided written informed consent.”

direct quote[Ethics statements, Ethical approval]

“…was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.”

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported, including approval from ethics committees, informed consent, and compliance with the Declaration of Helsinki and Good Clinical Practice.

Evidence

direct quote[Ethics statements]

direct quote[Methods, Study design and participants]

“All patients provided written informed consent.”

direct quote[Abstract, Trial registration]

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223).”

PASSReviewer 3· 95% conf

The study reports ethics approval from each study centre's ethics committee, written informed consent from patients, and compliance with the Declaration of Helsinki and Good Clinical Practice guidelines.

Evidence

direct quote[Ethics statements]

direct quote[Methods, 'Study design and participants']

“All patients provided written informed consent.”

Pyrotinib (400 mg orally once daily), placebo, trastuzumab (8/6 mg/kg IV), and docetaxel (75 mg/m2) are all named with dose, route, and schedule. The manufacturer for pyrotinib/placebo is implied by the sponsor (Jiangsu Hengrui Pharmaceuticals). SAS software version 9.4 is identified. No antibodies, cell lines, or organisms are used that would require additional authentication.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The investigational drug (pyrotinib, placebo) and key biological resources (trastuzumab, docetaxel) are adequately identified with regimen details.

Evidence

direct quote[Methods, Procedures, paragraph 1]

“Patients were randomly assigned … to receive either oral pyrotinib (400 mg once daily) or placebo, both combined with intravenous trastuzumab (8 mg/kg in treatment cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel on day 1 of each 21 day treatment cycle.”

direct quote[Methods, Statistical analysis, final paragraph]

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

direct quote[Abstract]

“…both in combination with intravenous trastuzumab (8 mg/kg for the first cycle, then 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day treatment cycle.”

PASSReviewer 2· 90% conf

The investigational product (pyrotinib) and comparator (placebo) are identified, and the statistical software is named with version. Other wet-lab resources are not applicable.

Evidence

direct quote[Abstract, Interventions]

“Eligible patients were randomly assigned in a 1:1 ratio to receive either the irreversible pan-HER inhibitor pyrotinib (400 mg orally once daily) or placebo, both in combination with intravenous trastuzumab (8 mg/kg for the first cycle, then 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day treatment cycle.”

direct quote[Methods, Statistical analysis]

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

PASSReviewer 3· 85% conf

The investigational products (pyrotinib, trastuzumab, docetaxel) are identified by name, dose, and regimen. The statistical software (SAS version 9.4) is identified. Other biological resources (antibodies, cell lines) are not used.

Evidence

direct quote[Abstract, 'Interventions']

“Pyrotinib (400 mg orally once daily) or placebo, both in combination with intravenous trastuzumab (8 mg/kg for the first cycle, then 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day treatment cycle.”

direct quote[Methods, 'Statistical analysis']

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

The Kaplan-Meier method, stratified log-rank test, and Cox proportional hazards model are specified for time-to-event endpoints. Proportions are compared using the Cochran-Mantel-Haenszel method. Software (SAS 9.4) is identified. Exact p-values (e.g., P=0.004, P<0.001) and hazard ratios with 95% CIs are provided throughout. Data presentation includes Kaplan-Meier curves and forest plots with per-group n. No arithmetic errors were detected. The paper correctly notes that p-values for overall survival are nominal and from a non-prespecified analysis.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 97% conf

Statistical methods are rigorous and appropriate for a phase 3 trial. All key tests are named, effect sizes with CIs are reported, and p-values are exact.

Evidence

direct quote[Abstract, Results]

“Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004).”

direct quote[Methods, Statistical analysis]

“The Kaplan-Meier method was used to estimate the time-to-event endpoints … with differences between groups assessed using the stratified log-rank test, and hazard ratios … determined using the stratified Cox proportional hazards model.”

direct quote[Methods, Statistical analysis]

“All statistical analyses were performed using SAS (SAS Institute), version 9.4 or higher.”

PASSReviewer 2· 90% conf

Statistical methods are well-described and appropriate for a phase 3 trial, including named tests, a pre-specified analysis plan, and reporting of hazard ratios with confidence intervals.

Evidence

direct quote[Methods, Statistical analysis]

“The Kaplan-Meier method was used to estimate the time-to-event endpoints, including progression-free survival, overall survival, and duration of response, and the Brookmeyer Crowley method was used to calculate the corresponding 95% confidence intervals (CIs).”

direct quote[Abstract, Results]

“Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004).”

direct quote[Methods, Statistical analysis]

“Prespecified interim analysis and final analysis of progression-free survival were to be conducted when about 275 events (67% of the expected events) and 410 events had occurred, respectively, and the superiority boundaries were set following the Lan-DeMets (O’Brien-Fleming) alpha spending function.”

PASSReviewer 3· 85% conf

Statistical tests are named (stratified log-rank test, stratified Cox proportional hazards model, Cochran-Mantel-Haenszel method), exact p-values are reported for primary analyses, software is identified, and data presentation includes Kaplan-Meier curves with hazard ratios and confidence intervals.

Evidence

direct quote[Methods, 'Statistical analysis']

“Differences between groups assessed using the stratified log-rank test, and hazard ratios and corresponding 95% CIs determined using the stratified Cox proportional hazards model.”

direct quote[Abstract, 'Results']

“Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004).”

The data availability statement provides a concrete route to anonymised individual patient data via Mendeley Data with a DOI. This is more specific than a vague "on request" statement and meets the threshold for reported_and_adequate. No custom code was written that would require a separate repository; the methods describe standard statistical software.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

Data availability is concretely stated with a DOI link to Mendeley Data. Code sharing is not applicable as the analysis used standard SAS procedures described in the paper and a statistical analysis plan provided in the supplement.

Evidence

direct quote[Data availability statement]

“The anonymised individual patient data supporting the findings of this study are available in the Mendeley Data ( https://data.mendeley.com/datasets/62224ppy2z/1 ).”

PASSReviewer 2· 95% conf

Data availability is well-addressed with a statement and a repository link for anonymized individual patient data. Code sharing is not applicable as the analysis used standard SAS procedures.

Evidence

direct quote[Data availability statement]

“The anonymised individual patient data supporting the findings of this study are available in the Mendeley Data ( https://data.mendeley.com/datasets/62224ppy2z/1 ).”

PASSReviewer 3· 90% conf

A data availability statement is present with a persistent DOI to a public repository (Mendeley Data) for anonymised individual patient data. Clinical trial registration number is provided.

Evidence

direct quote[Data availability statement]

“The anonymised individual patient data supporting the findings of this study are available in the Mendeley Data ( https://data.mendeley.com/datasets/62224ppy2z/1 ).”

direct quote[Abstract, 'Trial registration']

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223).”

The trial is registered at ClinicalTrials.gov (NCT03863223). The methods section is comprehensive and replicable. Limitations explicitly discussed include the absence of a pertuzumab control, un-reached median OS, and need for biomarker studies. All prespecified outcomes (PFS, OS, ORR, DOR, CBR, safety) are reported. Conclusions appropriately state superiority of the pyrotinib regimen, qualified by the nominal p-value for OS. Funding sources and competing interests are transparently reported.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 98% conf

Reporting is transparent: trial is registered (NCT03863223), methods are detailed, limitations are discussed, conclusions are proportional to the evidence, and funding/competing interests are fully declared.

Evidence

direct quote[Abstract, Trial registration]

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223).”

direct quote[Discussion, Limitations of this study]

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

direct quote[Funding; Competing interests]

“This study was funded by Jiangsu Hengrui Pharmaceuticals …”

PASSReviewer 2· 95% conf

Reporting is transparent and complete, with a trial registration, detailed methods, a discussion of limitations, and proportional conclusions.

Evidence

direct quote[Abstract, Trial registration]

“Trial registration ClinicalTrials.gov NCT03863223 (https://clinicaltrials.gov/ct2/show/NCT03863223).”

direct quote[Discussion, Limitations of this study]

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

direct quote[Funding and Competing interests sections]

“Funding: This study was funded by Jiangsu Hengrui Pharmaceuticals, with partial support from the National Natural Science Foundation of China (92459304), CAMS Innovation Fund for Medical Sciences (CIFMS; 2021-I2M-1-014), and National High Level Hospital Clinical Research Funding (2025-LYZX-D-A02).”

PASSReviewer 3· 90% conf

Methods are detailed for replication, the trial is registered, limitations are discussed, and conclusions are proportional. Funding and conflicts of interest are transparently reported. No formal reporting guideline checklist (CONSORT) is mentioned, which is common in journal publications.

Evidence

direct quote[Methods section]

“Full details of the study are reported elsewhere.”

direct quote[Discussion, 'Limitations of this study']

“One of the major limitations of this study was the absence of a control group using pertuzumab-trastuzumab combination treatment.”

direct quote[Funding and Competing interests sections]

“This study was funded by Jiangsu Hengrui Pharmaceuticals…”

7 copyedit issues flagged: mostly other, typo, consistency.

Checked 25 references: 25 verified.

Reproducibility

2 data/code links checked; 2 live.

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Adcurare Rigor Action ItemsFinal pass before journal submission

Ready to submit after minor revisions. The most critical pre-submission actions are to add a CONSORT checklist, clarify the proportional hazards assumption test, and fix the minor internal contradiction. The copyedit issues are minor and should be addressed for a clean submission.

1.
HIGHreporting
Add a completed CONSORT checklist as a supplementary file and mention adherence to CONSORT reporting guidelines in the Methods or Acknowledgments.
Clinical trial reporting standards require CONSORT adherence; its absence is a gap reviewers will flag.
2.
HIGHstatistics
In the Statistical analysis section, explicitly state that the proportional hazards assumption was tested (e.g., using Schoenfeld residuals) or provide a rationale for its acceptance (e.g., visual inspection of KM curves).
Two reviewers noted the lack of explicit assumption verification; adding this strengthens statistical rigor.
3.
HIGHreporting
Resolve the inconsistency in the reported median follow-up: Abstract states 35.7 months (pyrotinib) and 34.3 months (placebo), but Discussion states 'median follow-up of 35.9 months'.
This internal contradiction, flagged by the integrity lens, could confuse readers; align the numbers.
4.
MEDIUMother
Add a brief statement in the Methods (Statistical analysis) describing how outliers were defined and handled, even if none were excluded.
Two reviewers flagged outlier_handling as inadequate; a clear statement preempts reviewer questions.
5.
MEDIUMethics
Include the ethics committee protocol/approval number in the main text (e.g., Abstract or Methods) rather than only in a supplementary table.
One reviewer noted the irb_ethics_statement is inadequate; adding the number improves transparency.
6.
MEDIUMreporting
In the Discussion, briefly discuss the potential for confounding by post-discontinuation treatments despite documenting them, to strengthen OS interpretation.
Reviewer 1 suggested this to further strengthen transparency of the overall survival analysis.
7.
MEDIUMcopyedit
Fix the missing space before 'HER2' in the Conclusions: 'treatment ofHER2' should be 'treatment of HER2'.
Typographical error that could be caught during copyediting.
8.
MEDIUMcopyedit
Rephrase the Abstract conclusions: change 'superiority of pyrotinib … in sustaining longer progression-free survival' to 'superiority of a regimen of pyrotinib … in prolonging progression-free survival' for clarity.
The copyedit flagged this as slightly redundant; rewording improves readability.
9.
LOWcopyedit
In the Results, break the long sentence about treatment cycles into two for clarity (after 'placebo group').
Minor style improvement noted by the copyedit report.
10.
LOWcopyedit
Add a hyphen in 'anti-HER2 regimen' in the Conclusions for consistency with earlier usage (currently 'anti-HER2 regimen' appears without hyphen in one instance).
Minor consistency fix suggested by the copyedit report.

Full text (50,467 chars)Analyzed: Jul 6, 2026

Read alongside

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

Read full text (PMC)

Journal

DOI

10.1136/bmj-2025-087259

Share this Rigor Review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://adcurare.com/verify/5337e0d5-2cf6-4d7f-92b0-0b9412ca250d" target="_blank" rel="noopener">
  <img src="https://adcurare.com/verify/5337e0d5-2cf6-4d7f-92b0-0b9412ca250d/badge" alt="Adcurare Rigor Review — 4★ (Strong), 0 critical, 3 high issues for “Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Rigor Record.

Record fingerprint

0a4174dbce17e291c1f8003f7ab126a1c5d6adcfd264075699fec9a84ac037f7

Verify via API

Issued Jul 6, 2026Engine 7.6.0

Adcurare assesses methodological rigor, not the importance of the findings. See how we evaluate →